Strategies to Leverage Research Funding Guiding DOD's Peer Reviewed Medical Research Programs (2004) / Chapter Skim
Currently Skimming:
Appendix A: Selected Federal Programs with Nonfederal Funding Participation
Appendix A: Selected Federal Programs with Nonfederal Funding Participation
Pages 99-132
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 99... ...
A Selected Federal Programs with Nonfederal Funding Participation 1 DEPARTMENT OF DEFENSE (DOD) Dual Use Science and Technology (DUS&T)
|
From page 100... ...
, "The purpose of cost share is to ensure that the recipient incurs real risk that gives it a vested interest in theproject's success." TIAs also require "a greater level of involvement of the government program officials in the execution of the research than the usual oversight of a research grant or procurement contract." Twenty-eight TIAs and cooperative agreements were entered into in FY 2001, with industry paying for 46 percent of the total costs of $114 million (www.acq.osd.mil/dpap/Docs/FY01RPT.doc)
|
From page 101... ...
No cost sharing is required from academic institutions. Technologies for Metabolic Monitoring and Julia Weaver Fund Research Program www.momrp.org/tmm.jsp The Technologies for Metabolic Monitoring (TMM)
|
From page 102... ...
dtp.nci.nih.gov/docs/ap4/handbook/index.html Modeled after the Industry/University Cooperative Research Center Program of the National Science Foundation, AP4 is a partnership initiative whose goal is to conduct novel cancer therapeutic, prevention, diagnostic, and imaging research to hasten the translation of research findings into clinical trials. The research occurs at an academic center with the advice and support of industry, nonprofit institutes, government partners, and the National Cancer Institute (NCI)
|
From page 103... ...
grants.nih.gov/grants/guide/rfa-files/RFA-AG-04-005.html www.fnih.org/images/Prelim2003ar.pdf This public-private partnership initiative will develop a multisite, longitudinal, prospective, naturalistic study of normal cognitive aging, mild cognitive impairment, and early Alzheimer's disease as a public domain research resource. A primary goal of ADNI is to identify the biomarkers of disease progression that are most promising for use as surrogate endpoints in clinical trials.
|
From page 104... ...
Broder, Eli Lilly and Company Foundation, Novartis Pharmaceuticals Corporation, Pfizer Inc., Merck Company Foundation, and Wyeth. Merck made the first contribution of $1 million over three years, and pledges totaled $3.6 million at the end of 2003 (www.fnih.org/ images/Prelim2003ar.pdf)
|
From page 105... ...
Established in 1992 by NHLBI and the Cystic Fibrosis Foundation (CFF) , NHLBI issued an RFA for program project grants for research on gene therapy approaches to cystic fibrosis (CF)
|
From page 106... ...
JDRF intended to commit up to $250,000 in additional funds to cofund research project grants that are both scientifically meritorious and fit within the JDRF mission and research emphasis areas.
|
From page 107... ...
www.immunetolerance.org/ ITN is a consortium of approximately 80 basic and clinical scientists and physicians at more than 40 institutions in the United States, Canada, and Europe. Its purpose is to conduct basic and clinical trials on ways to improve the success of kidney transplants and pancreatic islet transplants by selectively disabling immune cells that attack transplanted tissues while allowing other immune cells to function normally and to induce tolerance in autoimmune diseases, asthma, and allergy.
|
From page 108... ...
This program was established to speed up the determination of the DNA sequence of the mouse genome and make the information available to the public quickly and without restrictions. Six NIH institutes (NCI, National Human Genome Research Institute, National Institute on Deafness and Other Communication Disorders, NIDDK, NINDS, NIMH)
|
From page 109... ...
. The effort was continued and broadened, and the international Mouse Genome Sequencing Consortium published a high-quality draft sequence of the mouse genome and a comparative analysis of the mouse and human genomes in the December 5, 2002, issue of Nature.
|
From page 110... ...
Partnerships: Hepatitis B and Vector Borne Diseases Control grants.nih.gov/grants/guide/rfa-files/RFA-AI-03-003.html In this partnership initiative, NIAID uses the U01 cooperative agreement funding mechanism to develop and test products for certain infectious diseases. A key component of this initiative is the development of productive partnerships between the federal government, universities, and the biotechnology, chemical, and/or pharmaceutical industries.
|
From page 111... ...
This initiative is aimed at stimulating industry to participate by providing funding that reduces investment risks for companies, for example, providing critical decisionmaking data for industry through support of antimicrobial screening; formulation, toxicology, and pharmacokinetics; regulatory filing; and clinical trials. Partnerships for Vaccine and Diagnostic Development grants.nih.gov/grants/guide/rfa-files/RFA-AI-03-028.html This initiative is basically the same as the Hepatitis B and Vector Borne Diseases Control partnership initiative except it is focused on the development of vaccines against and diagnostics for group A streptococci and group B streptococci and vaccines against Helicobacter pylori.
|
From page 112... ...
In addition, Siemens Medical is collaborating with the OAI by enabling the NIH discounted purchases of the 3T field-strength magnets for each of the clinical centers and working with NIH to insure the highest performance of these systems. Overcoming Barriers to Early Phase Clinical Trials Initiative www.focr.org/programs/publicprivate.htm www.fnih.org/partners/translational_research/overcomingbarriers.shtml In this public-private partnership, five industry partners (Aventis Pharmaceuticals Inc., Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation)
|
From page 113... ...
Translational Research for the Prevention and Control of Diabetes grants.nih.gov/grants/guide/pa-files/PA-02-153.html In 2002, this initiative was established to solicit research to translate recent advances in the prevention and treatment of type 1 or type 2 diabetes into clinical practice for individuals and communities at risk. It was formed by several NIH institutes (NIDDK, the National Eye Institute [NEI]
|
From page 114... ...
In September 2002, NIDDK, NINDS, NICHD, NINR, and JDRF awarded eight research grants relevant to hypoglycemia unawareness for funding periods of two to five years. The RFA for this initiative indicated that the NIH institutes intended to commit approximately $3.25 million in FY 2002 to fund four to eight grants, and that JDRF intended to commit up to $500,000 in additional funds to co-fund research project grants that are both scientifically meritorious and fit within their mission and research emphasis areas.
|
From page 115... ...
, and the American Digestive Health Foundation. Supports R01 research project grants; R29 FIRST awards; R03 small grants (RFA-DK-97-003)
|
From page 116... ...
Hartford Foundation, the Atlantic Philanthropies, and the Starr Foundation. Supports K23 patient-oriented research career development awards and K08 mentored clinical scientist development awards (RFA-AG-05-001)
|
From page 117... ...
Cost sharing at a level equal to 20 percent of the total amount requested from NSF is required and must be shown and
|
From page 118... ...
However, contributions counted as cost sharing toward projects of another federal agency may not be counted toward meeting the specific cost sharing requirements of the NSF award. The 2004 program solicitation (www.nsf.gov/pubs/2004/nsf04580/nsf04580.pdf)
|
From page 119... ...
In addition, contributions counted as cost sharing toward projects of another federal agency may not be counted toward meeting the cost-sharing requirement. The centers are funded by five-year cooperative agreements at between $1 million and $4 million a year, depending on the scope of the proposal, and they are eligible to compete for one five-year renewal.
|
From page 120... ...
Large Fortune 500 companies participating as a single firm must pay at least 60 percent of total project costs. Small and medium-sized companies working on single-firm projects are not required to provide cost sharing of direct costs but must pay a minimum of all indirect costs associated with the project.
|
From page 121... ...
www.alliance-cxca.org/ ACCP was established in 1999 by a Bill and Melinda Gates Foundation fiveyear, $50 million grant. Made up of five international organizations: International Agency for Research on Cancer, Pan American Health Organization, EngenderHealth, and JHPIEGO (affiliated with Johns Hopkins University)
|
From page 122... ...
Baylor's Human Genome Sequencing Center was the lead institution in a sequencing consortium that also includes Celera Genomics, Genome Therapeutics, The Institute for Genome Research, The University of Utah, Children's Hospital Oakland Research Institute, Medical College of Wisconsin, and University of British Columbia Genome Sciences Center. The Rat Genome Sequencing Consortium completed a rough draft of the sequence of the rat genome in November 2002.
|
From page 123... ...
International Malaria Genome Sequencing Consortium www.tigr.org/tdb/e2k1/pfa1/ This public-private consortium, the first multicenter international basic science collaboration in the malaria field, was formed in 1966 to sequence the genome of the human malaria parasite Plasmodium falciparum, clone 3D7. The 2The Therapeutic Development Network was established by CFF to conduct early-phase clinical studies with novel therapies for CF.
|
From page 124... ...
Its goal is to bring public, private, and philanthropic sector partners together to fund and provide managerial and logistical support for the discovery and development of new medicines to treat and prevent malaria in disease-endemic countries. Funding and support has been received from a number of organizations, including the Bill and Melinda Gates Foundation, ExxonMobil Corporation, International Federation of Pharmaceutical Manufacturers Associations, World Bank, Wellcome Trust, and the World Health Organization.
|
From page 125... ...
From the start of the program through 2003, 414 fellowships had been awarded, representing more than $53 million. STATE AND LOCAL GOVERNMENT California Breast Cancer Research Program (CBCRP)
|
From page 126... ...
CNSI received an NSF grant for $17.7 million over five years to establish a nanoscale science and engineering center. CITRIS is co-awardee with the University of
|
From page 127... ...
The Strategic Technology and Research (STAR) Fund assists researchers at Kansas Board of Regents' universities compete for federal and private grants by helping to provide matching funds.
|
From page 128... ...
One is the South Carolina Venture Capital Fund ($50 million total; up to $5 million equity, near-equity, and seed capital of up to $5 million or 15 percent of the committed capital of the South Carolina based investor, whichever is less)
|
From page 129... ...
It expanded to include electronics manufacturing and new materials, communications and networking, digital media, and information technology for the life sciences. The program provides grants for collaborative research partnerships with industry, in which companies provide matching funds and both parties share in the project's results.
|
From page 130... ...
Initially, GC required all matching to be from private sources, but this proved infeasible and eventually provincial government funds were allowed to be counted as matching. The provincial governments, however, have different capacities and willingness to provide matching funds.
|
From page 131... ...
Private sector and research institution partners have invested an additional $1.2 billion, bringing the total value of Challenge Fund supported research projects to more than $1.6 billion. Structural Genomics Consortium (SGC)
|
From page 132... ...
The second level of review and final decisions were made by a Joint Executive Committee cochaired by the Director General of Research Councils and the Director of the Wellcome Trust. The committee included representatives from the Wellcome Trust, the Research Councils and HEFCE, Scottish Higher Education Funding Council, Higher Education Funding Council for Wales, and Department of Higher Education & Further Education, Training and Employment, Northern Ireland.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.